|
|
Article: ARIAD Reports Third Quarter 2009 Development Progress and Financial Results.(Financial report)
- Article from:
- Business Wire
- Article date:
- November 5, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
~ SUCCEED Trial Full Patient Enrollment On Track for Year-end 2009
~ Proof-of-Concept Clinical Data of AP24534 to be Presented at ASH
CAMBRIDGE, Mass. -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the third quarter and nine months ended September 30, 2009 and provided an update on corporate developments.
SUCCEED Trial Full Enrollment Expected at Year-End
ARIAD reaffirmed that the global, Phase 3 SUCCEED trial of oral ridaforolimus in patients with metastatic soft tissue and bone sarcomas remains on track for full enrollment around year-end 2009.
The independent Data Monitoring Committee ...